Cancer Immunotherapy Market Size to be Worth USD 530.2 Billion by 2035; Rising Research in Cancer Immunotherapy to Fuel Market Growth

Download Sample

Published Date: January 2025

Cancer immunotherapy represents a new and bright approach to cancer treatment, whereby one's immune system is manipulated to battle malignant cells. The increasing research in cancer immunotherapy is expected to propel market growth during the forecast period.

Cancer Immunotherapy Market Segmentation Analysis:

By Product Type	Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others
By Cancer Type	Lung Cancer, Colorectal Cancer, Melanoma Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others
By End-User	Hospitals, Cancer Research Centers, and Others

Cancer Immunotherapy Market Report Highlights:

The cancer immunotherapy market size is projected to reach USD 530.2 billion by 2034.
The market was valued at USD 158.5 billion in 2024.
The market is expected to expand at a CAGR of 14.2% during the forecast period.
North America holds the largest share in the market.
Asia Pacific is expected to witness fast growth during the forecast period.
By product type, the monoclonal antibodies segment is expected to lead the market during the forecast period.
On the basis of cancer type, lung cancer is the most dominant segment in the market.
Based on end-user, the market is being led by the hospitals segment.

Cancer Immunotherapy Market Dynamics:

Growth Factor	Challenge Factor	Market Trend
Rising Prevalence of Cancer	High Treatment Costs	Growing Treatment Indications

Cancer Immunotherapy Market Key Highlights:

In June 2024, a new phase 2 research started to examine a triple medication combination for pancreatic cancer. The University of Glasgow and the NHS Greater Glasgow and Clyde have initiated a mid-stage trial to test a new drug combination as a first-line treatment for patients with metastatic pancreatic cancer. The phase 2 PRIMUS-006 study, part of the Precision-Panc Platform, will evaluate Eli Lilly and Genentech's Gemzar (gemcitabine) in combination with Merck & Co's Keytruda (pembrolizumab), known as MSD outside the U.S. and Canada, and Immodulon Therapeutics' investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
In April 2024, Hope beckons as the first homegrown cell therapy for cancer treatment is announced. President Droupadi Murmu introduced India's first indigenously developed CAR T-cell therapy for cancer treatment, calling it a "breakthrough" that will give humanity new hope in the fight against the disease. NexCAR19 CAR T-cell therapy is the country's first 'Made in India' cell therapy, and it will considerably reduce cancer treatment costs. This gene-based therapy, developed by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre, aims to cure several types of cancer.

Cancer Immunotherapy Market Report Analysis:

Different types of immunotherapy with their respective examples applied in various cancers-

	Types of Immunotherapy	Examples
Cancer Immunotherapy	Naked monoclonal antibodies	Alemtuzumab is used to treat some patients suffering from Chronic Lymphocytic leukemia.
	Conjugated antibodies	Brentuximab vedotin binds to CD30 antigen, used against Hodgkin’s lymphoma.
	Bispecific monoclonal antibodies	Blinatumomab, whose one half binds to CD19 and the other half binds to CD3, used to treat acute lymphocytic leukemia.
	Immune checkpoint inhibitors	Monoclonal antibody blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) with ipilimumab.
	Non-specific immunotherapy	Some interleukins and interferons are used in: • IFN-α for use against hairy cell leukemia. • IL-2 is approved to treat advanced kidney cancer and metastatic melanoma
	Targeted vaccine therapy Tumor cell vaccine Antigen vaccine Peptide-based vaccine DNA-based vaccine Dendritic cell vaccine	Sipuleucel-T (Provenge) is a dendritic cell vaccine, used to treat advanced prostate cancer.

Browse ∼37 market data tables and ∼39 figures through ∼167 slides and in-depth TOC on “Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), End-User (Hospitals, Cancer Research Centers, and Others), and Region - Trends, Analysis and Forecast till 2034”

For more insights into the Cancer Immunotherapy Market and its future trends, visit the link: https://www.prophecymarketinsights.com/market_insight/cancer-immunotherapy-market-5559

Cancer Immunotherapy Market Competitive Landscape:

The major players operating in the cancer immunotherapy market include Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, and Immunocore, Ltd.